XML 57 R33.htm IDEA: XBRL DOCUMENT v3.26.1
Stock Compensation and Earnings (Loss) per Share (Tables)
 3 Months Ended
Mar. 31, 2026
Share-Based Payment Arrangement [Abstract]  
Schedule of restricted stock shares activity
Activity related to the Company’s equity compensation, which includes the Company’s restricted stock units (“RSUs”) and performance stock units (“PSUs”), was as follows:

(in thousands, except weighted average grant price)
Number of Shares
Weighted Average Grant Price
Outstanding awards, December 31, 2025
1,187 $15.39 
Granted664 13.18 
Vested(421)15.93 
Forfeited(9)15.63 
Outstanding awards, March 31, 2026
1,421 $14.20 
Activity related to the Company’s Relative Total Shareholder Return RSUs (“RTSRs”) was as follows:

(in thousands, except weighted average grant price)
Number of Shares
Weighted Average Grant Price
Outstanding awards, December 31, 2025
360 $15.77 
Granted118 13.42 
Vested— — 
Forfeited— — 
Outstanding awards, March 31, 2026
478 $15.19 
Schedule of stock compensation expense
Stock-based compensation expense was as follows:

 Three Months Ended
March 31,
(in thousands)20262025
Stock compensation expense$4,971 $3,897 
Capitalized stock compensation(173)(180)
Stock compensation expense, net$4,798 $3,717 
Schedule of Earnings Per Share, Basic and Diluted
The following table indicates the computation of basic and diluted earnings (loss) per share:

Three Months Ended
March 31,
(in thousands, except per share amounts)20262025
Calculation of net loss income per share:
Net loss$(15,751)$(9,132)
Amounts attributable to common shareholders
Net loss attributable to common shareholders
$(17,328)$(10,604)
Basic and diluted weighted average shares outstanding55,554 54,959 
Per share amounts attributable to common shareholders
Net loss per share$(0.31)$(0.19)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share The following table presents potentially dilutive instruments:
Three Months Ended
March 31,
(in thousands)20262025
Potentially dilutive shares related to the Series A Preferred Stock
3,743 3,492 
Potentially dilutive equity awards
687 450 
Total potentially dilutive instruments4,430 3,942